CClinicalTrials.gg
CompletedNCT07212179InsuLearn-SMAUpdated May 11, 2026

Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery

An interventional study of AID + InsuLearn-SMA and AID + CC in Type 1 Diabetes, sponsored by Melissa J. Schoelwer. Completed at 1 site in United States. Open to participants aged 14 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Melissa J. Schoelwer · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
14 Years to 21 Years
Sex
All
01

Study summary

To evaluate the safety and feasibility of a novel self-learning bolus calculator along with simplified meal announcement (AID+InsuLearn-SMA) in adolescents and young adults with T1D using Automated Insulin Delivery.

Read the detailed description

Following recruitment and screening, participants will be randomized to one of two sequences during the Hotel Admission: AID+InsuLearn-SMA→AID+CC or AID+CC→AID+InsuLearn-SMA. All participants will be trained on the study equipment, which includes (i) the DiAs smartphone running the Control-IQ algorithm with either the InsuLearn-SMA bolus calculator or the standard carbohydrate counting bolus calculator, and (ii) the Dexcom CGM. All participants will complete 7 days/6 nights run-in At-Home Period using the AID+CC system (Control-IQ with the standard carbohydrate counting bolus calculator). Participants will then undergo a 2-night supervised hotel admission (approximately 48 hours). During this admission, each participant will consume two standardized meals (dinner and breakfast), during which either the InsuLearn-SMA bolus calculator or the standard CC bolus calculator will be used in a randomized order. Two lunches will be offered during the Hotel Admission but not included in the analysis. Following discharge, all participants will complete 7 days/6 nights At-Home Period using the AID+InsuLearn-SMA system before returning the study equipment. The INSPIRE Questionnaire will be administered before and after the Hotel Admission. Additionally, participants will be asked to provide a 2-week CGM data download of their usual care for statistical analysis before randomization and after returning the equipment.

02

Conditions studied

  • Type 1 Diabetes

Keywords

  • Type 1 Diabetes (T1D)
  • Automated Insulin Delivery (AID)
  • Continuous Glucose Monitor (CGM)
  • Diabetes Assistant (DiAs)
  • Carbohydrate Counting (CC)
  • Simplified Meal Announcement (SMA)
03

In context

Diabetes Mellitus, Type 1

3,522 studies on the registry are indexed under Diabetes Mellitus, Type 1; 577 are open to participants now.

This study's enrollment of 2 is below the median of 40 across 2,649 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

This is the only study on the registry with Melissa J. Schoelwer as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥14.0 and ≤21 years old at time of consent
  2. HbA1c ≤ 10%.
  3. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year
  4. Having used an insulin pump within the last three months.
  5. Currently using insulin for at least six months
  6. Willingness to use insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections
  7. Willingness to switch to a commercially approved insulin (e.g. lispro or aspart or biosimilar approved products) within the study pump as directed by the study team.
  8. Has one or more supportive caregivers or companions living with the participant who are knowledgeable about emergency procedures for treatment of severe hypoglycemia and able to contact emergency services and study staff.
  9. Acceptable forms of contraception for participants of child-bearing potential include hormonal treatments including IUD, abstinence from heterosexual intercourse, vasectomy in partner, barrier methods (e.g. condom or diaphragm).
  10. For females, not currently known to be pregnant or breastfeeding. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
  11. Willingness to use the study InsuLearn system (CGM, pump, and phone) during the study period.
  12. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial.
  13. Access to internet at home and ability to upload data during the study as needed.
  14. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol.
  15. Participant is proficient in reading and writing English.

Exclusion criteria

Exclusion Criteria:

  1. History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment
  2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment
  3. Pregnancy or intent to become pregnant during the trial
  4. Currently breastfeeding or planning to breastfeed
  5. Currently being treated for a seizure disorder
  6. Planned surgery during study duration
  7. History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted)
  8. Treatment with any non-insulin glucose-lowering agent (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals)
  9. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol.
  10. Participation in another interventional trial at the time of enrollment.
  11. Visual impairment/blindness that prevents proper interaction with study equipment
  12. Participant who may have a falsely eligible HbA1c due to medical conditions or blood donations.
  13. Participants in whom the G6 CGM may be inaccurate due to interference.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    AID + InsuLearn-SMA

    Participant will use their Automated insulin delivery (AID) system \[insulin pump\] along with InsuLearn simplified meal announcement bolus calculator

    Device: AID + InsuLearn-SMA

  • Placebo comparator
    Carbohydrate Counting

    Participant will use their Automated insulin delivery (AID) system \[insulin pump\] and their usual carbohydrate counting bolus calculator

    Device: AID + CC

Interventions

  • DeviceAID + InsuLearn-SMA

    Automated insulin delivery (AID) system with InsuLearn simplified meal announcement bolus calculator

  • DeviceAID + CC

    Automated insulin delivery (AID) system using usual carbohydrate counting bolus calculator

06

What researchers measure

Primary outcomes

  1. TIR (70-180 mg/dL)

    The primary outcome will be the CGM-measured time in range (TIR, 70-180 mg/dL) during the hotel portion.

    Time frame: 18 hours

Secondary outcomes

  1. TIR (70-180 mg/dL)

    The primary outcome will be the CGM-measured time in range (TIR, 70-180 mg/dL) during the at-home period.

    Time frame: 1-week

07

Study locations

1 site
  • University of Virginia Center for Diabetes Technology
    Charlottesville, Virginia 22903-2981, United States
08

References and documents

Study documents

  • Informed consent form · Mar 11, 2026

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07212179
Lead sponsor
Melissa J. Schoelwer
Responsible party
Melissa J. Schoelwer (Investigator, University of Virginia) — Sponsor-investigator
First posted
Oct 8, 2025
Start date
Mar 3, 2026
Primary completion
Apr 14, 2026
Completion
Apr 15, 2026
Last update
May 11, 2026

Study contacts

Melissa Schoelwer, MD
principal investigator · University of Virginia School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion